Literature DB >> 30542710

miR‑144‑3p regulates the resistance of lung cancer to cisplatin by targeting Nrf2.

Yan Yin1, Hua Liu2, Junhui Xu1, Dongsheng Shi1, Liang Zhai1, Bin Liu1, Lei Wang1, Guangxin Liu1, Jianwen Qin1.   

Abstract

Chemotherapeutic drug resistance is correlated with treatment failure and poor prognosis among lung cancer patients. Numerous studies indicate the relevance of miRNAs in inducing certain drug resistance. In the course of the study, we unexpectedly found that miR‑144‑3p could regulate the cisplatin resistance of lung cancer cells via Nrf2. However, Nrf2 also could reverse activate the expression of miR‑144‑3p by binding to the ARE box in the miR‑144‑3p promoter. This may be a self‑protection mechanism of the body. In addition, we also found that in other cancer cell lines, such as HepG2, miR‑144‑3p also had the function of regulating cisplatin resistance. These findings may provide some theoretical reference for the clinical inhibition of cisplatin resistance.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30542710     DOI: 10.3892/or.2018.6772

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  14 in total

Review 1.  Non-coding RNAs in ferroptotic cancer cell death pathway: meet the new masters.

Authors:  Mehdi Rabiee Valashedi; Chia Bamshad; Nima Najafi-Ghalehlou; Amirsadegh Nikoo; Kazuo Tomita; Yoshikazu Kuwahara; Tomoaki Sato; Amaneh Mohammadi Roushandeh; Mehryar Habibi Roudkenar
Journal:  Hum Cell       Date:  2022-04-12       Impact factor: 4.174

2.  Regulation of VEGFA, KRAS, and NFE2L2 Oncogenes by MicroRNAs in Head and Neck Cancer.

Authors:  Caroline Izak Cuzziol; Ludimila Leite Marzochi; Vitória Scavacini Possebon; Rosa Sayoko Kawasaki-Oyama; Marlon Fraga Mattos; Vilson Serafim Junior; Letícia Antunes Muniz Ferreira; Érika Cristina Pavarino; Márcia Maria Urbanin Castanhole-Nunes; Eny Maria Goloni-Bertollo
Journal:  Int J Mol Sci       Date:  2022-07-05       Impact factor: 6.208

Review 3.  Genetic and epigenetic regulation of the NRF2-KEAP1 pathway in human lung cancer.

Authors:  Nuria Camiña; Trevor M Penning
Journal:  Br J Cancer       Date:  2021-11-29       Impact factor: 9.075

4.  Downregulation of RKIP promotes radioresistance of nasopharyngeal carcinoma by activating NRF2/NQO1 axis via downregulating miR-450b-5p.

Authors:  Wei Huang; Guangqing Shi; Zhong Yong; Jian Li; Juan Qiu; Yan Cao; Yongfeng Zhao; Li Yuan
Journal:  Cell Death Dis       Date:  2020-07-06       Impact factor: 8.469

Review 5.  Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression.

Authors:  Lei Zhang; Xiulan Zheng; Wen Cheng; Xuefei Zhang; Lingling Wang; Haixia Li
Journal:  Cell Death Dis       Date:  2020-07-24       Impact factor: 8.469

6.  MicroRNA-362-5p enhances the cisplatin sensitivity of gastric cancer cells by targeting suppressor of zeste 12 protein.

Authors:  Xiaoli Wei; Mengru Gao; Yaser Ahmed; Min Gao; Wenbo Liu; Yiyin Zhang; Xiaoque Xie; Qihong Zhao; Hua Wang; Kangsheng Gu
Journal:  Oncol Lett       Date:  2019-06-19       Impact factor: 2.967

Review 7.  Revisiting cancer hallmarks: insights from the interplay between oxidative stress and non-coding RNAs.

Authors:  Li Zhou; Zhe Zhang; Zhao Huang; Edouard Nice; Bingwen Zou; Canhua Huang
Journal:  Mol Biomed       Date:  2020-08-31

8.  LncRNA HLA Complex Group 11 Knockdown Alleviates Cisplatin Resistance in Gastric Cancer by Targeting the miR-144-3p/UBE2D1 Axis.

Authors:  Yu Li; Liqin Wang; Xiaoyi Xu; Heng Sun; Leilei Wu
Journal:  Cancer Manag Res       Date:  2021-10-01       Impact factor: 3.989

Review 9.  Crosstalk of MicroRNAs and Oxidative Stress in the Pathogenesis of Cancer.

Authors:  Can Lu; Danting Zhou; Qiang Wang; Wenliang Liu; Fenglei Yu; Fang Wu; Chen Chen
Journal:  Oxid Med Cell Longev       Date:  2020-04-28       Impact factor: 6.543

10.  TOP2A promotes proliferation and metastasis of hepatocellular carcinoma regulated by miR-144-3p.

Authors:  Tao Wang; Jing Lu; Rangrang Wang; Wanyue Cao; Junming Xu
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.